JP2019512216A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512216A5 JP2019512216A5 JP2018544213A JP2018544213A JP2019512216A5 JP 2019512216 A5 JP2019512216 A5 JP 2019512216A5 JP 2018544213 A JP2018544213 A JP 2018544213A JP 2018544213 A JP2018544213 A JP 2018544213A JP 2019512216 A5 JP2019512216 A5 JP 2019512216A5
- Authority
- JP
- Japan
- Prior art keywords
- functional fragment
- polypeptide
- calcium channel
- inhibiting
- orai1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 46
- 229920001184 polypeptide Polymers 0.000 claims 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims 33
- 108090000312 Calcium Channels Proteins 0.000 claims 22
- 102000003922 Calcium Channels Human genes 0.000 claims 22
- 238000000034 method Methods 0.000 claims 16
- 230000002401 inhibitory effect Effects 0.000 claims 12
- 101150060735 orai1 gene Proteins 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 230000009460 calcium influx Effects 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 101000899089 Homo sapiens BPI fold-containing family A member 1 Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000004071 biological effect Effects 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102000051040 human BPIFA1 Human genes 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 230000036428 airway hyperreactivity Effects 0.000 claims 2
- 210000005091 airway smooth muscle Anatomy 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000016160 smooth muscle contraction Effects 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298204P | 2016-02-22 | 2016-02-22 | |
| US62/298,204 | 2016-02-22 | ||
| PCT/US2017/018840 WO2017147128A1 (en) | 2016-02-22 | 2017-02-22 | Peptide inhibitors of calcium channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019512216A JP2019512216A (ja) | 2019-05-16 |
| JP2019512216A5 true JP2019512216A5 (OSRAM) | 2020-04-09 |
Family
ID=59685595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544213A Pending JP2019512216A (ja) | 2016-02-22 | 2017-02-22 | カルシウムチャネルのペプチド阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10894811B2 (OSRAM) |
| EP (1) | EP3419994B1 (OSRAM) |
| JP (1) | JP2019512216A (OSRAM) |
| AU (1) | AU2017222450A1 (OSRAM) |
| BR (1) | BR112018017144A2 (OSRAM) |
| ES (1) | ES2979122T3 (OSRAM) |
| IL (1) | IL261265A (OSRAM) |
| MX (1) | MX2018010132A (OSRAM) |
| WO (1) | WO2017147128A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018111903A1 (en) * | 2016-12-13 | 2018-06-21 | Spyryx Biociences, Inc. | Saline formulations of splunc1 peptides |
| EP4314010A4 (en) * | 2021-03-22 | 2025-03-05 | The University of North Carolina at Chapel Hill | MODIFIED PEPTIDOMIMETICS AND METHODS OF USE |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3023787A1 (de) | 1980-06-25 | 1982-01-21 | Studiengesellschaft Kohle mbH, 4330 Mülheim | Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| JP2627899B2 (ja) | 1987-08-19 | 1997-07-09 | 株式会社 ビタミン研究所 | 遺伝子封入リポソームの製法 |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| DK0452457T3 (da) | 1989-11-03 | 1998-03-02 | Univ Vanderbilt | Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| JP2001500015A (ja) | 1996-09-06 | 2001-01-09 | トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法 |
| CA2271325A1 (en) | 1996-11-12 | 1998-05-22 | The Regents Of The University Of California | Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery |
| DE60101305D1 (de) * | 2000-02-24 | 2004-01-08 | Oxford Glycosciences Uk Ltd | Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten |
| US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
| WO2005056045A1 (en) * | 2003-12-04 | 2005-06-23 | The University Of Iowa Research Foundation | Methods and compositions related to plunc polypeptides |
| DE102004031579B4 (de) * | 2004-06-29 | 2012-12-27 | Forschungsverbund Berlin E.V. | Peptide zur Inhibition der Interaktion von Proteinkinase A und Proteinkinase A-Ankerproteinen, diese umfassendes Nukleinsäuremolekül, Vektor, Wirtszelle, gegen diese gerichtetes Erkennungsmolekül, diese enthaltende pharmazeutische Zusammensetzung, diese enthaltender Kit und deren Verwendung |
| BR112014006535A2 (pt) * | 2011-09-20 | 2017-03-28 | Univ North Carolina Chapel Hill | regulação dos canais de sódio através das proteínas plunc |
-
2017
- 2017-02-22 ES ES17757105T patent/ES2979122T3/es active Active
- 2017-02-22 EP EP17757105.6A patent/EP3419994B1/en active Active
- 2017-02-22 US US16/078,397 patent/US10894811B2/en active Active
- 2017-02-22 JP JP2018544213A patent/JP2019512216A/ja active Pending
- 2017-02-22 WO PCT/US2017/018840 patent/WO2017147128A1/en not_active Ceased
- 2017-02-22 BR BR112018017144A patent/BR112018017144A2/pt not_active IP Right Cessation
- 2017-02-22 AU AU2017222450A patent/AU2017222450A1/en not_active Abandoned
- 2017-02-22 MX MX2018010132A patent/MX2018010132A/es unknown
-
2018
- 2018-08-21 IL IL261265A patent/IL261265A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2661500T3 (es) | Variantes de HMGB1 y sus usos | |
| JP2020040969A5 (OSRAM) | ||
| NZ601868A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| JP2015134796A5 (OSRAM) | ||
| NZ593281A (en) | Sparc binding peptides and uses thereof | |
| NZ599161A (en) | Method for activation of helper t cell and composition for use in the method | |
| JP2013529087A5 (OSRAM) | ||
| JP2012515778A5 (OSRAM) | ||
| JP2016516016A5 (OSRAM) | ||
| JPWO2019156137A5 (OSRAM) | ||
| JPWO2019107530A5 (OSRAM) | ||
| US20200071370A1 (en) | Cell penetrating peptides that inhibit irf5 nuclear localization | |
| JP2015522264A5 (OSRAM) | ||
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| NZ602845A (en) | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof | |
| WO2013097704A1 (zh) | 多肽在制备治疗或预防类风湿性关节炎药物中的应用 | |
| JP2013510169A5 (OSRAM) | ||
| MX2008009493A (es) | Peptido novedoso y uso del mismo. | |
| JP2012529293A5 (OSRAM) | ||
| NZ610620A (en) | Inhibitors of apoptosis and uses thereof | |
| JP2017052783A5 (OSRAM) | ||
| JP2020513810A5 (OSRAM) | ||
| NZ590469A (en) | Treatment of rheumatoid arthritis with human beta defensins (1-4) | |
| JP2019512216A5 (OSRAM) | ||
| JP2017500316A5 (OSRAM) |